Sofia Pezet, a teenager from Montreal, has become the first minor in Quebec to receive CAR-T cell therapy, a revolutionary cancer treatment that reprograms a patient's own immune cells to attack cancer. Her successful treatment is now helping open the door for other young patients to access this cutting-edge therapy.
Breakthrough Treatment
CAR-T cell therapy, which stands for chimeric antigen receptor T-cell therapy, involves extracting a patient's T-cells, genetically modifying them in a lab to recognize and fight cancer, and then infusing them back into the patient. The therapy has shown remarkable results in certain blood cancers, but its use in minors has been limited. Sofia's case marks a milestone for pediatric oncology in Quebec.
According to the Montreal Children’s Hospital, where the treatment was administered, Sofia was diagnosed with a form of leukemia that had not responded to conventional treatments. The hospital's oncology team worked closely with regulatory authorities to secure approval for the therapy, which is typically reserved for adults or clinical trials.
Impact and Future Access
Sofia's successful treatment is expected to accelerate the adoption of CAR-T cell therapy for minors in Quebec. “This is a game-changer for pediatric cancer care,” said Dr. Marie-Claude Bélanger, the lead oncologist on Sofia's case. “Sofia’s positive outcome demonstrates that this therapy can be safely and effectively used in younger patients.” The hospital plans to expand the program to treat additional children with similar conditions.
Advocates hope that Sofia's story will encourage more funding and research into pediatric applications of CAR-T therapy. The Quebec Ministry of Health has indicated it will review guidelines to facilitate access for minors, potentially reducing the time to treatment for future patients.
